Bausch Health Companies Inc (NYSE: BHC) has experienced a rise in its stock price by 2.20 compared to its previous closing price of 6.2. However, the company has seen a gain of 10.58% in its stock price over the last five trading days. 247wallst.com reported 2025-06-24 that We have to consider that insiders buying their stock wouldn’t put up their own money unless they believed the move would be profitable.
Is It Worth Investing in Bausch Health Companies Inc (NYSE: BHC) Right Now?
The 36-month beta value for BHC is at 0.33. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for BHC is 290.67M, and currently, shorts hold a 2.96% of that float. The average trading volume for BHC on June 25, 2025 was 2.49M shares.
BHC’s Market Performance
BHC stock saw an increase of 10.58% in the past week, with a monthly gain of 42.39% and a quarterly increase of -9.48%. The volatility ratio for the week is 3.91%, and the volatility levels for the last 30 days are 3.02% for Bausch Health Companies Inc (BHC). The simple moving average for the past 20 days is 19.33% for BHC’s stock, with a -8.33% simple moving average for the past 200 days.
Analysts’ Opinion of BHC
Many brokerage firms have already submitted their reports for BHC stocks, with Piper Sandler repeating the rating for BHC by listing it as a “Underweight.” The predicted price for BHC in the upcoming period, according to Piper Sandler is $3 based on the research report published on August 02, 2024 of the previous year 2024.
Raymond James, on the other hand, stated in their research note that they expect to see BHC reach a price target of $8. The rating they have provided for BHC stocks is “Mkt Perform” according to the report published on July 10th, 2024.
Jefferies gave a rating of “Buy” to BHC, setting the target price at $16 in the report published on September 20th of the previous year.
BHC Trading at 25.78% from the 50-Day Moving Average
After a stumble in the market that brought BHC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.67% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BHC starting from Paulson John, who purchase 3,564,059 shares at the price of $5.94 back on Jun 13 ’25. After this action, Paulson John now owns 32,791,702 shares of Bausch Health Companies Inc, valued at $21,170,510 using the latest closing price.
Paulson John, the Director of Bausch Health Companies Inc, purchase 1,005,376 shares at $5.47 during a trade that took place back on Jun 12 ’25, which means that Paulson John is holding 29,227,643 shares at $5,499,407 based on the most recent closing price.
Stock Fundamentals for BHC
Current profitability levels for the company are sitting at:
- 0.16 for the present operating margin
- 0.65 for the gross margin
The net margin for Bausch Health Companies Inc stands at -0.0. The total capital return value is set at 0.06.
Currently, EBITDA for the company is 1.55 billion with net debt to EBITDA at -0.45. When we switch over and look at the enterprise to sales, we see a ratio of 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.35.
Conclusion
In conclusion, Bausch Health Companies Inc (BHC) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
